Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab Combined With RC48-ADC in Radiotherapy for HER-2 Positive MIBC
NCT07279597Phase 2Not yet recruiting
- Sponsor
- Tongji Hospital
- Start
- Dec 2025
- Primary completion
- Dec 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Antibody-Drug Conjugates (ADCs)
01
Overview
Phase 2, open-label, single-arm trial of disitamab vedotin and toripalimab in bladder carcinoma, sponsored by Tongji Hospital. Primary endpoint: Complete Response. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
disitamab vedotintoripalimab
03
Conditions
bladder carcinoma
Beyond the preview
Go deeper on NCT07279597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07279597.